首页> Multiple sclerosis (Houndmills, Basingstoke, England)> De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Annette M,Langer-Gould

第一单位： Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, CA, USA; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.

作者： Annette M,Langer-Gould ^[1] ; Jessica B,Smith ^[2] ; Allen Scott,Nielsen ^[3] ; Brandon E,Beaber ^[4] ; Sonu M,Brara ^[5] ; Samira,Amirova ^[6] ; Elaine,Su ^[6] ; Bonnie H,Li ^[2] ; Neda,Z Esfahani ^[7] ; Fernando,Torres ^[8] ; Stanley,Xu ^[9]

作者单位： Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, CA, USA; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. ^[1] Department of Research & Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA. ^[2] Department of Neurology, Fontana Medical Center, Southern California Permanente Medical Group, Fontana, CA, USA. ^[3] Department of Neurology, Downey Medical Center, Southern California Permanente Medical Group, Downey, CA, USA. ^[4] Department of Neurology, Panorama City Medical Center, Southern California Permanente Medical Group, Panorama City, CA, USA. ^[5] Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, CA, USA. ^[6] Department of Neurology, Capitol Hill Medical Office, Washington Permanente Medical Group, Seattle, WA, USA. ^[7] Department of Radiology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, CA, USA. ^[8] Department of Research & Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. ^[9]

关键词 Multiple sclerosis de-escalation disease modifying therapies extended dosing rituximab